English
Home > Products > CAS NO 22876-20-6

China CAS NO 22876-20-6 Factory

We have been also specializing in improving the things administration and QC system to ensure that we could preserve terrific gain within the fiercely-competitive company for CAS NO 22876-20-6,22876-20-6,6-Chloro-2-benzoxazolethiol, We welcome new and old customers to contact us by phone or send us inquiries by mail for future business relationships and achieving mutual success.
CAS NO 22876-20-6, Our solutions are mainly exported to Europe, Africa, America, the Middle East and Southeast Asia and other countries and regions. We now have enjoyed a great reputation among our customers for quality products and good services.We would make friends with businessmen from at home and abroad, following the purpose of "Quality First, Reputation First, the Best Services."

Related Products

Hot Products

  • 1-Chlorododecane

    1-Chlorododecane

    Product Name:1-Chlorododecane
    Molecular Formula:C12H25Cl
    Molecular Weight:204.78
    CAS Registry Number:112-52-7
  • Elobixibat

    Elobixibat

    Name:Elobixibat Molecular Formula:C36H45N3O7S2 CAS Registry Number:439087-18-0
  • 2-Iodo-5-phenylpyridine

    2-Iodo-5-phenylpyridine

    Product Name:2-Iodo-5-phenylpyridine
    Molecular Formula:C11H8IN
    Molecular Weight:281.09
    CAS Registry Number:120281-56-3
  • 2'-Deoxyadenosine 5'-phosphate

    2'-Deoxyadenosine 5'-phosphate

    Product Name:2'-Deoxyadenosine 5'-phosphate
    Molecular Formula:C10H14N5O6P
    Molecular Weight:331.22
    CAS Registry Number:653-63-4
  • Filgotinib

    Filgotinib

    Product Name:Filgotinib
    Molecular Formula:C21H23N5O3S
    Molecular Weight;425.5
    CAS Registry Number;1206161-97-8
  • 4-Fluorobenzyl alcohol

    4-Fluorobenzyl alcohol

    Product Name:4-Fluorobenzyl alcohol
    Molecular Formula:C7H7FO
    Molecular Weight:126.13
    CAS Registry Number:459-56-3
  • Related Blog
  • Reviews

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    Here are so many diseases that affect the human population in the current hours and so are the numerous drugs that are available to treat those diseases.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept